Zions Bancorporation National Association UT Takes $960,000 Position in Certara, Inc. (NASDAQ:CERT)

Key Points

• Zions Bancorporation National Association UT has acquired a new position in Certara, Inc., purchasing 96,966 shares valued at approximately $960,000.
• Certara's stock has seen a decline of 2.8% and currently trades at $10.94, with a market capitalization of $1.76 billion.
• Analysts have mixed ratings on Certara, with a consensus rating of "Moderate Buy" and a target price of $15.14, reflecting uncertainty in its future performance.

Zions Bancorporation National Association UT bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 96,966 shares of the company's stock, valued at approximately $960,000. Zions Bancorporation National Association UT owned about 0.06% of Certara as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of CERT. ArrowMark Colorado Holdings LLC grew its position in shares of Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after acquiring an additional 3,861,674 shares during the period. Ameriprise Financial Inc. lifted its stake in Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the last quarter. Mackenzie Financial Corp bought a new position in Certara during the fourth quarter worth about $17,852,000. Royce & Associates LP acquired a new position in Certara during the first quarter worth approximately $4,439,000. Finally, Gotham Asset Management LLC raised its stake in Certara by 590.1% in the fourth quarter. Gotham Asset Management LLC now owns 431,326 shares of the company's stock valued at $4,594,000 after buying an additional 368,821 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Trading Down 2.1%

CERT traded down $0.24 during trading on Thursday, reaching $10.94. 350,700 shares of the company's stock were exchanged, compared to its average volume of 1,726,693. The firm has a fifty day moving average price of $10.89 and a two-hundred day moving average price of $11.72. The stock has a market capitalization of $1.76 billion, a PE ratio of 218.74 and a beta of 1.42. Certara, Inc. has a one year low of $8.64 and a one year high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%. The company had revenue of $104.57 million for the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the business earned $0.07 earnings per share. Certara's revenue was up 12.1% compared to the same quarter last year. As a group, equities research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CERT shares. KeyCorp dropped their price target on Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. UBS Group reduced their price target on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Morgan Stanley assumed coverage on Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price for the company. Finally, JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Certara has a consensus rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.